Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases

Background The optimal duration, safety, and benefit of preoperative chemotherapy in patients with colorectal liver metastases (CLM) are unclear. We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab,...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Kishi, Yoji (author)
مؤلفون آخرون: Zorzi, Daria (author), Contreras, Carlo (author), Maru, Dipen (author), Kopetz, Scott (author), Ribero, Dario (author), Motta, Manuela (author), Ravarino, Nicoletta (author), Risio, Mauro (author), Curley, Steven (author), Abdalla, Eddie (author), Capussotti, Lorenzo (author), Vauthey, Jean-Nicolas (author)
التنسيق: article
منشور في: 2010
الوصول للمادة أونلاين:http://hdl.handle.net/10725/2618
http://dx.doi.org/10.1245/s10434-010-1166-1
http://link.springer.com/article/10.1245/s10434-010-1166-1
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513458731483136
author Kishi, Yoji
author2 Zorzi, Daria
Contreras, Carlo
Maru, Dipen
Kopetz, Scott
Ribero, Dario
Motta, Manuela
Ravarino, Nicoletta
Risio, Mauro
Curley, Steven
Abdalla, Eddie
Capussotti, Lorenzo
Vauthey, Jean-Nicolas
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author_facet Kishi, Yoji
Zorzi, Daria
Contreras, Carlo
Maru, Dipen
Kopetz, Scott
Ribero, Dario
Motta, Manuela
Ravarino, Nicoletta
Risio, Mauro
Curley, Steven
Abdalla, Eddie
Capussotti, Lorenzo
Vauthey, Jean-Nicolas
author_role author
dc.creator.none.fl_str_mv Kishi, Yoji
Zorzi, Daria
Contreras, Carlo
Maru, Dipen
Kopetz, Scott
Ribero, Dario
Motta, Manuela
Ravarino, Nicoletta
Risio, Mauro
Curley, Steven
Abdalla, Eddie
Capussotti, Lorenzo
Vauthey, Jean-Nicolas
dc.date.none.fl_str_mv 2010
2015-11-19T08:45:04Z
2015-11-19T08:45:04Z
2015-11-19
dc.identifier.none.fl_str_mv 1068-9265
http://hdl.handle.net/10725/2618
http://dx.doi.org/10.1245/s10434-010-1166-1
Kishi, Y., Zorzi, D., Contreras, C. M., Maru, D. M., Kopetz, S., Ribero, D., ... & Vauthey, J. N. (2010). Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of surgical oncology, 17(11), 2870-2876.
http://link.springer.com/article/10.1245/s10434-010-1166-1
dc.language.none.fl_str_mv en
dc.relation.none.fl_str_mv Annals of Surgical Oncology
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.title.none.fl_str_mv Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description Background The optimal duration, safety, and benefit of preoperative chemotherapy in patients with colorectal liver metastases (CLM) are unclear. We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM. Methods A total of 219 patients underwent hepatic resection following FOLFOX with or without bevacizumab and were divided into 2 groups according to the chemotherapy duration: 1–8 cycles (short duration [SD]; N = 157) and ≥9 cycles (long duration [LD]; N = 62). The frequency of complete or major pathologic response, sinusoidal injury, and major postoperative morbidity were compared. Results Treatment consisting of ≥9 cycles was not associated with an increase in complete or major pathologic response (SD vs. LD, 57% vs. 55%; P = .74). The incidence of sinusoidal injury was higher in the LD group (26% vs. 42%; P = .017). The incidence of liver insufficiency was higher in the LD group (4% vs. 11%; P = .035). Sinusoidal injury did not predict postoperative liver insufficiency; multivariate analysis revealed ≥9 cycles was the only independent predictor of postoperative liver insufficiency (P = .031; odds ratio = 3.90). Chemotherapy including bevacizumab was associated with a significantly higher frequency of complete or major response in both SD and LD groups. Conclusions Extended preoperative chemotherapy increases the risk of hepatotoxicity in CLM without improving the pathologic response. The type of chemotherapy (FOLFOX with bevacizumab) has more impact on pathologic response than the duration of chemotherapy.Background The optimal duration, safety, and benefit of preoperative chemotherapy in patients with colorectal liver metastases (CLM) are unclear. We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM. Methods A total of 219 patients underwent hepatic resection following FOLFOX with or without bevacizumab and were divided into 2 groups according to the chemotherapy duration: 1–8 cycles (short duration [SD]; N = 157) and ≥9 cycles (long duration [LD]; N = 62). The frequency of complete or major pathologic response, sinusoidal injury, and major postoperative morbidity were compared. Results Treatment consisting of ≥9 cycles was not associated with an increase in complete or major pathologic response (SD vs. LD, 57% vs. 55%; P = .74). The incidence of sinusoidal injury was higher in the LD group (26% vs. 42%; P = .017). The incidence of liver insufficiency was higher in the LD group (4% vs. 11%; P = .035). Sinusoidal injury did not predict postoperative liver insufficiency; multivariate analysis revealed ≥9 cycles was the only independent predictor of postoperative liver insufficiency (P = .031; odds ratio = 3.90). Chemotherapy including bevacizumab was associated with a significantly higher frequency of complete or major response in both SD and LD groups. Conclusions Extended preoperative chemotherapy increases the risk of hepatotoxicity in CLM without improving the pathologic response. The type of chemotherapy (FOLFOX with bevacizumab) has more impact on pathologic response than the duration of chemotherapy.
eu_rights_str_mv openAccess
format article
id LAURepo_9c074e704513048a9b351d9a2184f33a
identifier_str_mv 1068-9265
Kishi, Y., Zorzi, D., Contreras, C. M., Maru, D. M., Kopetz, S., Ribero, D., ... & Vauthey, J. N. (2010). Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of surgical oncology, 17(11), 2870-2876.
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/2618
publishDate 2010
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver MetastasesKishi, YojiZorzi, DariaContreras, CarloMaru, DipenKopetz, ScottRibero, DarioMotta, ManuelaRavarino, NicolettaRisio, MauroCurley, StevenAbdalla, EddieCapussotti, LorenzoVauthey, Jean-NicolasBackground The optimal duration, safety, and benefit of preoperative chemotherapy in patients with colorectal liver metastases (CLM) are unclear. We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM. Methods A total of 219 patients underwent hepatic resection following FOLFOX with or without bevacizumab and were divided into 2 groups according to the chemotherapy duration: 1–8 cycles (short duration [SD]; N = 157) and ≥9 cycles (long duration [LD]; N = 62). The frequency of complete or major pathologic response, sinusoidal injury, and major postoperative morbidity were compared. Results Treatment consisting of ≥9 cycles was not associated with an increase in complete or major pathologic response (SD vs. LD, 57% vs. 55%; P = .74). The incidence of sinusoidal injury was higher in the LD group (26% vs. 42%; P = .017). The incidence of liver insufficiency was higher in the LD group (4% vs. 11%; P = .035). Sinusoidal injury did not predict postoperative liver insufficiency; multivariate analysis revealed ≥9 cycles was the only independent predictor of postoperative liver insufficiency (P = .031; odds ratio = 3.90). Chemotherapy including bevacizumab was associated with a significantly higher frequency of complete or major response in both SD and LD groups. Conclusions Extended preoperative chemotherapy increases the risk of hepatotoxicity in CLM without improving the pathologic response. The type of chemotherapy (FOLFOX with bevacizumab) has more impact on pathologic response than the duration of chemotherapy.Background The optimal duration, safety, and benefit of preoperative chemotherapy in patients with colorectal liver metastases (CLM) are unclear. We evaluated the association between the duration of preoperative chemotherapy with 5-fluorouracil (5-FU), leucovorin, oxaliplatin (FOLFOX) ± bevacizumab, pathologic response, and hepatotoxicity after hepatic resection for CLM. Methods A total of 219 patients underwent hepatic resection following FOLFOX with or without bevacizumab and were divided into 2 groups according to the chemotherapy duration: 1–8 cycles (short duration [SD]; N = 157) and ≥9 cycles (long duration [LD]; N = 62). The frequency of complete or major pathologic response, sinusoidal injury, and major postoperative morbidity were compared. Results Treatment consisting of ≥9 cycles was not associated with an increase in complete or major pathologic response (SD vs. LD, 57% vs. 55%; P = .74). The incidence of sinusoidal injury was higher in the LD group (26% vs. 42%; P = .017). The incidence of liver insufficiency was higher in the LD group (4% vs. 11%; P = .035). Sinusoidal injury did not predict postoperative liver insufficiency; multivariate analysis revealed ≥9 cycles was the only independent predictor of postoperative liver insufficiency (P = .031; odds ratio = 3.90). Chemotherapy including bevacizumab was associated with a significantly higher frequency of complete or major response in both SD and LD groups. Conclusions Extended preoperative chemotherapy increases the risk of hepatotoxicity in CLM without improving the pathologic response. The type of chemotherapy (FOLFOX with bevacizumab) has more impact on pathologic response than the duration of chemotherapy.PublishedN/A2015-11-19T08:45:04Z2015-11-19T08:45:04Z20102015-11-19Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1068-9265http://hdl.handle.net/10725/2618http://dx.doi.org/10.1245/s10434-010-1166-1Kishi, Y., Zorzi, D., Contreras, C. M., Maru, D. M., Kopetz, S., Ribero, D., ... & Vauthey, J. N. (2010). Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Annals of surgical oncology, 17(11), 2870-2876.http://link.springer.com/article/10.1245/s10434-010-1166-1enAnnals of Surgical Oncologyinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/26182019-02-26T08:27:25Z
spellingShingle Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
Kishi, Yoji
status_str publishedVersion
title Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
title_full Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
title_fullStr Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
title_full_unstemmed Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
title_short Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
title_sort Extended Preoperative Chemotherapy Does Not Improve Pathologic Response and Increases Postoperative Liver Insufficiency After Hepatic Resection for Colorectal Liver Metastases
url http://hdl.handle.net/10725/2618
http://dx.doi.org/10.1245/s10434-010-1166-1
http://link.springer.com/article/10.1245/s10434-010-1166-1